Biose Industrie begins its LBP manufacturing expansion into the US with new Boston office
Boston is one of the top global hubs for biotechnology companies developing live biotherapeutic products (LBPs), and many of these companies seek out the expertise of the world leading CDMO, […]
Biose Industrie Initiaties Large-Scale Production of Biomica’s 4-Strain Candidate Consortium in its Immuno-Oncology Program
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live […]
Biose Industrie and strain characterisation – Growing and developing our service offering through strategic sponsoring of research projects
A company that supports the process development and manufacturing of live biotherapeutic products (LBPs) needs to know bacteria inside out: not just the potential therapeutic effects of the strains, but […]
How Biose Industrie aims to extend its lead in LBP manufacturing with 30-million Euro investment
Live biotherapeutic products (LBPs), or live microorganisms employed as drugs, are relatively new on the pharmaceutical scene. Yet Biose Industrie CEO Adrien Nivoliez has his eye on the future. According […]
Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota
Aurillac, July 16, 2020 – Biose Industrie announced today the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the […]
When drug manufacturers take on living medicines
Contract Development & Manufacturing Organizations (CDMOs) are critical partners for moving ahead with new drug products. But with a growing number of start-up companies working to develop microbiome-based products, are CDMOs ready to […]